Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis

[1]  Y. Hosomi,et al.  Survival update in randomized phase II trial of S-1/cisplatin (SP) or docetaxel/cisplatin (DP) with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (NSCLC)-TORG1018. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  T. Yamanaka,et al.  A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L , 2018, British Journal of Cancer.

[3]  Building Healthy Academic Communities BHAC Journal.  Board of Directors , 2018, Building Healthy Academic Communities Journal.

[4]  M. Hossen,et al.  119P Cisplatin/etoposide or paclitaxel/carboplatin with concurrent radiation therapy in stage IIIB non-small cell lung cancer: A one-year phase II trial at a low resource setting , 2018 .

[5]  H. Ohmatsu,et al.  Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer , 2018, Cancer Chemotherapy and Pharmacology.

[6]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[7]  Jinming Yu,et al.  A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation. , 2017 .

[8]  Wei Chen,et al.  Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  R. Govindan,et al.  PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2016, Journal of Clinical Oncology.

[10]  Jian Zhang,et al.  Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer , 2016, Oncotarget.

[11]  A. Ades,et al.  Automated generation of node‐splitting models for assessment of inconsistency in network meta‐analysis , 2015, Research synthesis methods.

[12]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[13]  Joseph Beyene,et al.  Network Meta-Analysis Using R: A Review of Currently Available Automated Packages , 2014, PloS one.

[14]  Y. Tomizawa,et al.  Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. , 2013, Lung cancer.

[15]  Youngchul Kim,et al.  A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401 , 2013, Cancer Chemotherapy and Pharmacology.

[16]  Panagiota Spyridonos,et al.  Graphical Tools for Network Meta-Analysis in STATA , 2013, PloS one.

[17]  C. Obasaju,et al.  Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  M. Maemondo,et al.  Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601. , 2013, Lung cancer.

[19]  Tae Hyun Kim,et al.  Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. , 2013, International journal of radiation oncology, biology, physics.

[20]  Shixiu Wu,et al.  Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. , 2012, Lung cancer.

[21]  T. Yamanaka,et al.  S-1 Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Multi-Institutional Phase II Trial (West Japan Thoracic Oncology Group 3706) , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[23]  Benjamin Movsas,et al.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. , 2011, Journal of the National Cancer Institute.

[24]  R. Govindan,et al.  Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Masaaki Kawahara,et al.  Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Keitaro Matsuo,et al.  Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[28]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Groen,et al.  Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  S. Thibodeau,et al.  Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. , 2005, Chest.

[31]  Andrew Gelman,et al.  General methods for monitoring convergence of iterative simulations , 1998 .

[32]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[33]  D. Rubin,et al.  Inference from Iterative Simulation Using Multiple Sequences , 1992 .

[34]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[35]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.